TPEX:6615

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Sofiva GenomicsLtd

Market Cap

NT$1.1b

Last Updated

2021/06/17 23:02 UTC

Data Sources

Company Financials

Executive Summary

Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. More Details


Snowflake Analysis

Flawless balance sheet with questionable track record.

Share Price & News

How has Sofiva GenomicsLtd's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6615 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 6615's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

2.3%

6615

-0.1%

TW Healthcare

1.3%

TW Market


1 Year Return

-22.1%

6615

11.8%

TW Healthcare

48.5%

TW Market

Return vs Industry: 6615 underperformed the TW Healthcare industry which returned 11.9% over the past year.

Return vs Market: 6615 underperformed the TW Market which returned 48.1% over the past year.


Shareholder returns

6615IndustryMarket
7 Day2.3%-0.1%1.3%
30 Day13.5%3.1%8.1%
90 Day6.5%1.1%8.0%
1 Year-19.0%-22.1%15.3%11.8%53.3%48.5%
3 Year-55.4%-58.8%46.9%32.6%75.9%55.7%
5 Yearn/a78.5%48.6%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Sofiva GenomicsLtd's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sofiva GenomicsLtd undervalued compared to its fair value and its price relative to the market?

34.01x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 6615 (NT$53) is trading above our estimate of fair value (NT$51.67)

Significantly Below Fair Value: 6615 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6615 is poor value based on its PE Ratio (34x) compared to the TW Healthcare industry average (16.8x).

PE vs Market: 6615 is poor value based on its PE Ratio (34x) compared to the TW market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6615's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6615 is overvalued based on its PB Ratio (2.1x) compared to the TW Healthcare industry average (1.9x).


Future Growth

How is Sofiva GenomicsLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sofiva GenomicsLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sofiva GenomicsLtd performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6615 has high quality earnings.

Growing Profit Margin: 6615's current net profit margins (6.7%) are lower than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: 6615's earnings have grown by 3.7% per year over the past 5 years.

Accelerating Growth: 6615's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6615 had negative earnings growth (-44.1%) over the past year, making it difficult to compare to the Healthcare industry average (-2.6%).


Return on Equity

High ROE: 6615's Return on Equity (6.1%) is considered low.


Financial Health

How is Sofiva GenomicsLtd's financial position?


Financial Position Analysis

Short Term Liabilities: 6615's short term assets (NT$338.7M) exceed its short term liabilities (NT$126.7M).

Long Term Liabilities: 6615's short term assets (NT$338.7M) exceed its long term liabilities (NT$85.2M).


Debt to Equity History and Analysis

Debt Level: 6615's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: 6615's debt to equity ratio has reduced from 15.3% to 0.1% over the past 5 years.

Debt Coverage: 6615's debt is well covered by operating cash flow (10393.9%).

Interest Coverage: 6615's interest payments on its debt are well covered by EBIT (13.5x coverage).


Balance Sheet


Dividend

What is Sofiva GenomicsLtd current dividend yield, its reliability and sustainability?

2.64%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 6615's dividend (2.64%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).

High Dividend: 6615's dividend (2.64%) is low compared to the top 25% of dividend payers in the TW market (5.01%).


Stability and Growth of Payments

Stable Dividend: 6615 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 6615 has only been paying a dividend for 4 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (89.8%), 6615's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Sofiva GenomicsLtd has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sofiva Genomics Co.,Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sofiva Genomics Co.,Ltd.
  • Ticker: 6615
  • Exchange: TPEX
  • Founded: 2012
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: NT$1.127b
  • Shares outstanding: 21.26m
  • Website: https://www.sofivagenomics.com.tw

Number of Employees


Location

  • Sofiva Genomics Co.,Ltd.
  • No. 27, Baoqing Road
  • Zhongzheng District
  • Taipei
  • 10043
  • Taiwan

Listings


Biography

Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. The company offers prenatal services, including thalassemia carrier screening; tests for microdeletion syndromes an...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 23:02
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.